相关实验视频

Updated: Jun 3, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

TRPA1作为癌症治疗点的潜力-使用生物信息工具进行的一项研究

¹Department of Anatomy, Biophysics and Physiology, Faculty of Biology, University of Bucharest, Spl. Independentei 91-95, 050095 Bucharest, Romania.

Pharmaceuticals (Basel, Switzerland)

|January 8, 2025

概括

暂时受体潜能1 (TRPA1) 基因的基因.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物信息学是一种生物信息学.

背景情况:

暂时受体潜能1 (TRPA1) 基因表达在固体瘤中升高.
已知TRPA1在炎症,氧化应激和有毒物质反应中的作用,但其在癌症中的临床相关性尚不清楚.
关于TRPA1与癌症阶段,转移和免疫细胞透的关联的了解有限.

研究的目的:

通过生物信息学分析,研究TRPA1在各种癌症中的作用.
为了将TRPA1表达与临床参数相关联,包括癌症阶段,转移和免疫细胞透.
探索TRPA1作为癌症治疗点的潜力.

主要方法:

对公开可用的数据集进行生物信息分析 (TCGA,TIMER,GEPIA,UALCAN).
量化TRPA1mRNA表达和生存分析.
分析TRPA1高甲基化及其与免疫细胞透的相关性.

主要成果:

TRPA1基因在许多癌症类型中表现出高甲基化.
高TRPA1表达与某些癌症的更好的预后有关,与阶段和转移相关,但在其他癌症中充当亲瘤基因.
TRPA1表达影响免疫细胞透,并与参与炎症,氧化应激和细胞运动的基因有关.

结论:

这项研究为跨越多种瘤的TRPA1基因调节提供了新的见解.
在癌症中TRPA1的双重作用需要进一步的研究.
TRPA1为癌症治疗提供了潜在的治疗点.

关键词:

在4-HNE中,我们的PDAC是PDAC.在 TRPA1 中,它是 TRPA1 .胰腺腺癌的癌症.

更多相关视频

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...